Untreated AMD worsens vision

Article

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Delaying treatment in patients with subfoveal neovascular age-related macular degeneration (wet AMD) correlates to progressive and substantial loss of visual acuity (VA), according to a report published online ahead of print by Eye.

Luis Arias, MD of Bellvitge University Hospital, Barcelona, Spain and colleagues conducted a retrospective, multicentre, epidemiological study of patients referred to retina specialists following a diagnosis of wet AMD.

The researchers found that the median time period elapsing between diagnosis and the first treatment visit was 2.3 months, and the percentage of patients with a VA of 20/400 or worse doubled from diagnosis (12.4%) to initial treatment visit (24.7%). Length of time between diagnosis and treatment showed a high statistically significant correlation to VA degeneration.

The team concluded that substantial VA loss results from untreated wet AMD.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.